



IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Robert H. Zimmer) Examiner:
)
Serial No.: 10/825,472) Group Art Unit: 1617
)
Filed: April 15, 2004) Confirmation No. 8345

For: **Compositions and Methods for Enhanced Pharmacological Activity of
Compositions Comprising Peptide Drug Substance**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

The Information Disclosure Statement submitted herewith is being filed, to the best of applicant's knowledge, before the mailing date of a first Office Action on the merits.

The filing of this Information Disclosure Statement shall not be construed to be a representation that a search has been conducted, nor shall it be construed as an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

Serial No. 10/825,472

Attorney Docket: 98204.00024

It is respectfully requested that the Examiner return a copy of the attached form PTO-1449 with initials or other appropriate marks indicating consideration of the cited materials.

Respectfully submitted,

Date: October 5, 2004



Basam E. Nabulsi
Reg. No. 31,645
Attorney for Applicants

McCARTER & ENGLISH, LLP
CityPlace I
185 Asylum Street, 36th Floor
Hartford, CT 06103-3495
(203) 965-0601


I hereby certify that the enclosed Information Disclosure Statement along with a PTO-1449 Form and the cited references are being deposited with the United States Postal Service as first class mail, postage prepaid, addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on October 5, 2004.

Dated: October 5, 2004


Joan Simmons

HARTFORD: 624202.01

Form PTO-1449 (modified 2/91)	U.S. DEPT OF COMMERCE Patent and Trademark Office	Attorney Docket Number: 98204.00024	Serial No.: 10/825,472
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicants:	
		Robert H. Zimmer	
		Filing date: 4/15/04	Group Art Unit: 1617



U.S. PATENT DOCUMENTS

Examiner Initial	Patent number	Date	Inventor	Class	Sub class	Filing date if appropriate
	4,239,754	12/16/1980	Sache et al.			
	4,336,534	6/22/1982	Kumagai			
	4,339,534	7/13/1982	Johansen et al.			
	4,396,606	8/2/1983	Goldstein			
	4,694,006	9/15/1987	Bundgaard et al.			
	4,925,673	5/15/1990	Steiner et al.			
	5,212,158	5/18/1993	Vandai			
	6,136,952	10/24/2000	Li et al.			
	2002/0090603	7/11/2002	Lipton et al.			


FOREIGN PATENT DOCUMENTS

	Document number	Date	Country	Class	Sub class	Translation Yes No
WO	98/11126	3/19/1998	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Fukushima, K., Hypoglycemic Effect and Enhanced Gastrointestinal Absorption of Insulin Using New Cinnamoyl-phenylalanine Derivatives, Hokkaido Journal of Medical Science, Vol. 71, No. 6, 1996, pp. 727-743.
	Vergnolle, N., et al., Proteinase-Activated Receptor 2 (PAR ₂)-Activating Peptides: Identification of A Receptor Distinct From PAR ₂) That Regulates Intestinal, Transport, Proceedings of the National Academy of Sciences of USA, National Academy of Science, Vol. 95, June 1998 (1998-06), pp. 7766-7771.
	Langguth, P., et al., The Challenge of Proteolytic Enzymes in Intestinal Peptide Delivery, Journal of Controlled Release, Elsevier Science Publishers B.V. Amsterdam, NL, Vol. 46, No. 1, May 1997, pp. 39-57.
	Egleton, R.D., et al., Improved Bioavailability to the Brain of Glycosylated Met-Enkephalin Analogs, Brain Research, Vol. 881, NO. 1, 2000, pp. 37-46.
	Pauletti, G.M., et al., Improvement of Oral Peptide Bioavailability: Peptidomimetics and Prodrug Strategies, Advanced Drug Delivery Review, Vol. 27, No. 2-3, 1997, pp. 235-256.

Examiner:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

Form PTO-1449 (modified 2/91)	U.S. DEPT OF COMMERCE Patent and Trademark Office	Attorney Docket Number: 98204.00024	Serial No.: 10/825,472
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) 		Applicants: Robert H. Zimmer	
		Filing date: 4/15/04	Group Art Unit: 1617

U.S. PATENT DOCUMENTS

Examiner Initial	Patent number	Date	Inventor	Class	Sub class	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

Document number	Date	Country	Class	Sub class	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Ahlers, et al., Enhanced Immunogenicity of HIV-1 Vaccine Construct By Modification of the Native Peptide Sequence, Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 10856-10861, September 1997.
	Greenstein, et al., A Universal T Cell Epitope-Containing Peptide From Hepatitis B Surface Antigen Can Enhance Antibody Specific For HIV gp120, Journal of Immunology, Vol. 148, pp. 3970-3977, No. 12, June 1992.
	Belyakov, et al., The Importance of Local Mucosal HIV-Specific CD8 ⁺ Cytotoxic T Lymphocytes For Resistance to Mucosal Viral Transmission in Mice and Enhancement of Resistance by Local Administration of IL-12, The Journal of Clinical Investigation, Vol. 102(12); pp. 2072-2081, December 1998.
	Belyakov, et al., Mucosal Immunization With HIV-1 Peptide Vaccine Induces Mucosal and Systemic Cytotoxic T Lymphocytes and Protective Immunity In Mice Against Intrarectal Recombinant HIV_Vaccinia Challenge, Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 1709-1714, February 1998.
	Patel, et al., Oral Administration of Insulin By Encapsulation Within Liposomes, North-Holland Publishing Company, Volume 62, No. 1, pp. 60-63, February 1976.
	Hashimoto, et al., ACTH Release in Pituitary Cell Cultures, Effect of Neurogenic Peptides and Neurotransmitter Substances Corticotropin Releasing Factor (CRF), Endocrinol. Japan, Vol. 26 (1), pp. 103-109, February 1979.

Examiner:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	